GB201518172D0 - Colloidal particles for use in medicine - Google Patents

Colloidal particles for use in medicine

Info

Publication number
GB201518172D0
GB201518172D0 GBGB1518172.0A GB201518172A GB201518172D0 GB 201518172 D0 GB201518172 D0 GB 201518172D0 GB 201518172 A GB201518172 A GB 201518172A GB 201518172 D0 GB201518172 D0 GB 201518172D0
Authority
GB
United Kingdom
Prior art keywords
medicine
colloidal particles
colloidal
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1518172.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cantab Biopharmaceuticals Patents Ltd
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Priority to GBGB1518172.0A priority Critical patent/GB201518172D0/en
Publication of GB201518172D0 publication Critical patent/GB201518172D0/en
Priority to US15/768,381 priority patent/US20190192664A1/en
Priority to KR1020187013254A priority patent/KR20180067616A/ko
Priority to PCT/EP2016/074759 priority patent/WO2017064276A1/en
Priority to SG10202010711UA priority patent/SG10202010711UA/en
Priority to EP16781807.9A priority patent/EP3362039A1/en
Priority to EA201890703A priority patent/EA201890703A1/ru
Priority to MX2018004445A priority patent/MX391574B/es
Priority to BR112018007399A priority patent/BR112018007399A2/pt
Priority to AU2016336929A priority patent/AU2016336929B2/en
Priority to SG11201802956RA priority patent/SG11201802956RA/en
Priority to IL258567A priority patent/IL258567B2/en
Priority to JP2018519423A priority patent/JP7160678B2/ja
Priority to CN201680073237.XA priority patent/CN108472246A/zh
Priority to HK18115899.0A priority patent/HK1256814A1/zh
Priority to CA3036111A priority patent/CA3036111C/en
Priority to US16/883,338 priority patent/US20210093721A1/en
Priority to US18/752,365 priority patent/US20250170244A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1518172.0A 2015-10-14 2015-10-14 Colloidal particles for use in medicine Ceased GB201518172D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB1518172.0A GB201518172D0 (en) 2015-10-14 2015-10-14 Colloidal particles for use in medicine
CA3036111A CA3036111C (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine
BR112018007399A BR112018007399A2 (pt) 2015-10-14 2016-10-14 composição, método de tratamento, kit de partes e forma de dosagem
SG11201802956RA SG11201802956RA (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine
PCT/EP2016/074759 WO2017064276A1 (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine
SG10202010711UA SG10202010711UA (en) 2015-10-14 2016-10-14 Colloidal Particles for Use in Medicine
EP16781807.9A EP3362039A1 (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine
EA201890703A EA201890703A1 (ru) 2015-10-14 2016-10-14 Коллоидные частицы, предназначенные для применения в медицине
MX2018004445A MX391574B (es) 2015-10-14 2016-10-14 Partículas coloidales para su uso en medicina.
US15/768,381 US20190192664A1 (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine
AU2016336929A AU2016336929B2 (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine
KR1020187013254A KR20180067616A (ko) 2015-10-14 2016-10-14 약에 사용하기 위한 콜로이드 입자
IL258567A IL258567B2 (en) 2015-10-14 2016-10-14 A composition comprising a colloidal particle for use in the treatment of haemophilia a, a kit comprising threof and a dosage form threof
JP2018519423A JP7160678B2 (ja) 2015-10-14 2016-10-14 医薬用コロイド粒子
CN201680073237.XA CN108472246A (zh) 2015-10-14 2016-10-14 用于在药物中使用的胶体颗粒
HK18115899.0A HK1256814A1 (zh) 2015-10-14 2016-10-14 用於在药物中使用的胶体颗粒
US16/883,338 US20210093721A1 (en) 2015-10-14 2020-05-26 Colloidal particles for use in medicine
US18/752,365 US20250170244A1 (en) 2015-10-14 2024-06-24 Colloidal particles for use in medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1518172.0A GB201518172D0 (en) 2015-10-14 2015-10-14 Colloidal particles for use in medicine

Publications (1)

Publication Number Publication Date
GB201518172D0 true GB201518172D0 (en) 2015-11-25

Family

ID=55131025

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1518172.0A Ceased GB201518172D0 (en) 2015-10-14 2015-10-14 Colloidal particles for use in medicine

Country Status (15)

Country Link
US (3) US20190192664A1 (enExample)
EP (1) EP3362039A1 (enExample)
JP (1) JP7160678B2 (enExample)
KR (1) KR20180067616A (enExample)
CN (1) CN108472246A (enExample)
AU (1) AU2016336929B2 (enExample)
BR (1) BR112018007399A2 (enExample)
CA (1) CA3036111C (enExample)
EA (1) EA201890703A1 (enExample)
GB (1) GB201518172D0 (enExample)
HK (1) HK1256814A1 (enExample)
IL (1) IL258567B2 (enExample)
MX (1) MX391574B (enExample)
SG (2) SG11201802956RA (enExample)
WO (1) WO2017064276A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021092580A1 (en) * 2019-11-07 2021-05-14 The Board Of Trustees Of The University Of Illinois Peptides and methods of treating sepsis, atherosclerosis, thrombosis, stroke, heart attack and inflammation
GB202111757D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111759D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles
GB202111758D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69418334T2 (de) 1993-08-06 2000-01-27 Opperbas Holding B.V., Amsterdam Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
MXPA00010241A (es) 1998-04-27 2004-09-06 Opperbas Holding Bv Composicion farmaceutica que comprende el factor viii y liposomas neutrales..
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
RU2250911C2 (ru) 1999-07-14 2005-04-27 Элзэ Копэрейшн Липосомальная композиция, нейтральный липополимер и способ увеличения времени циркуляции липосомы
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
DE602004013769D1 (de) * 2003-04-15 2008-06-26 Opperbas Holding Bv Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
JP2008544990A (ja) * 2005-06-29 2008-12-11 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 低免疫原性蛋白質−脂質複合体に関する組成物および方法
AU2010255391C1 (en) 2009-06-03 2016-10-27 Sequessome Technology Holdings Limited Formulations for the treatment of deep tissue pain
MX336482B (es) 2009-08-21 2016-01-21 Henk-Andre Kroon Formulaciones vesiculares.
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
EP2838566A2 (en) 2012-04-16 2015-02-25 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
CN107879960B (zh) * 2013-03-08 2021-06-22 诺华股份有限公司 用于传递活性成分的脂质和脂质组合物

Also Published As

Publication number Publication date
SG10202010711UA (en) 2020-12-30
EP3362039A1 (en) 2018-08-22
CN108472246A (zh) 2018-08-31
AU2016336929B2 (en) 2022-09-29
IL258567B1 (en) 2025-04-01
WO2017064276A1 (en) 2017-04-20
CA3036111C (en) 2023-06-06
HK1256814A1 (zh) 2019-10-04
EA201890703A1 (ru) 2018-11-30
IL258567B2 (en) 2025-08-01
MX2018004445A (es) 2018-08-14
MX391574B (es) 2025-03-21
US20250170244A1 (en) 2025-05-29
SG11201802956RA (en) 2018-05-30
IL258567A (en) 2018-05-31
JP7160678B2 (ja) 2022-10-25
BR112018007399A2 (pt) 2018-10-16
AU2016336929A1 (en) 2018-05-10
CA3036111A1 (en) 2017-04-20
US20190192664A1 (en) 2019-06-27
US20210093721A1 (en) 2021-04-01
JP2018535952A (ja) 2018-12-06
KR20180067616A (ko) 2018-06-20

Similar Documents

Publication Publication Date Title
GB2524085B (en) Exception handling in microprocessor systems
IL252532A0 (en) Polycyclic carbamoylpyridone compounds and their pharmaceutical use
SG11201605896WA (en) Dihydropyrimidine compounds and their application in pharmaceuticals
SG11201700968PA (en) Formulation comprising particles
PL3046983T3 (pl) Wielowarstwowa cząstka ścierna
ZA201502203B (en) Nano particulate delivery system
IL251630A0 (en) Combined therapy for use in cancer treatment
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumors
IL251905B (en) Epilimod for use in the treatment of kidney cancer
IL250507A0 (en) Anti-ck8 antibodies for use in cancer therapy
EP3177304A4 (en) Therapeutic nanoparticles for accumulation in the brain
IL248424A0 (en) Neuroprotective substances and their uses
GB201521304D0 (en) Tokenisation in cardholder - not - present transactions
SG11201606034WA (en) Device for delivering particles
GB201701400D0 (en) Compound for use in medicine
IL258567A (en) Colloidal particles for use in medicine
PL3129057T3 (pl) Glikolipidy i ich kompozycje farmaceutyczne do stosowania w leczeniu
GB201516107D0 (en) Complexes and methods for their preparation
GB201616880D0 (en) Compound for use in medicine
GB201701388D0 (en) Compound for use in medicine
GB201416493D0 (en) Polypeptides for use in therapy
GB201404831D0 (en) Animalistic studies in nature
GB201409978D0 (en) Novel compounds and their use in therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)
S30Z Assignments for licence or security reasons

Free format text: APPLICANT. CANTAB BIOPHARMACEUTICALS PATENTS LIMITED SECURITY INTEREST. FONDS RUSNANO CAPITAL S.A.